TNF and rheumatoid arthritis: In other settings, i.e. patients with RA who had an inadequate response to disease-modifying antirheumatic drugs and a TNF inhibitor, tocilizumab proved more effective than rituximab in B cell-poor but not in B cell-rich patients (34).